WS Investor
20 Dec 2025, 20:04
Alnylam to Invest $250 Million to Expand U.S. Manufacturing Capacity for RNAi Therapeutics
Alnylam Pharmaceuticals announced plans to invest $250 million to expand its manufacturing facility in Norton, Massachusetts, adding a proprietary enzymatic ligation platform designed to significantly increase siRNA production capacity and lower manufacturing costs. The expansion is intended to support growing global demand and future product launches across Alnylam’s expanding RNAi pipeline.
The new siRELIS enzymatic ligation platform has been accepted into the U.S. Food and Drug Administration’s Emerging Technology Program, enabling accelerated regulatory engagement worldwide. Alnylam said the platform has already been validated through pilot-scale production of candidates including zilebesiran for hypertension-related cardiovascular risk and nucresiran for transthyretin-mediated amyloidosis, demonstrating its potential for scalable, high-quality manufacturing.
Construction at the 200,000-square-foot Norton facility is underway, with full operational capability expected by late 2027. The company said the investment will strengthen Massachusetts’ role as a global biomanufacturing hub, support high-quality job creation, and enable more sustainable, efficient large-scale production of RNAi therapeutics for patients worldwide.
Source: Alnylam Pharmaceuticals, Business Wire
Alnylam Pharmaceuticals announced plans to invest $250 million to expand its manufacturing facility in Norton, Massachusetts, adding a proprietary enzymatic ligation platform designed to significantly increase siRNA production capacity and lower manufacturing costs. The expansion is intended to support growing global demand and future product launches across Alnylam’s expanding RNAi pipeline.
The new siRELIS enzymatic ligation platform has been accepted into the U.S. Food and Drug Administration’s Emerging Technology Program, enabling accelerated regulatory engagement worldwide. Alnylam said the platform has already been validated through pilot-scale production of candidates including zilebesiran for hypertension-related cardiovascular risk and nucresiran for transthyretin-mediated amyloidosis, demonstrating its potential for scalable, high-quality manufacturing.
Construction at the 200,000-square-foot Norton facility is underway, with full operational capability expected by late 2027. The company said the investment will strengthen Massachusetts’ role as a global biomanufacturing hub, support high-quality job creation, and enable more sustainable, efficient large-scale production of RNAi therapeutics for patients worldwide.
Source: Alnylam Pharmaceuticals, Business Wire
